Atopic dermatitis involves a combination of skin barrier dysfunction and underlying Type 2 immune dysregulation, with cytokines such as interleukin-4 and interleukin-13 playing a central role. This immune activity drives the characteristic inflammation, itch and skin changes seen in the condition. Understanding this mechanism has informed the development of targeted biologic therapies for moderate-to-severe disease. Barrier dysfunction and immune dysregulation are thought to interact, each exacerbating the other over time.

Atopic dermatitis is associated with significant impacts on sleep quality due to persistent itch, alongside increased rates of anxiety and depression in affected patients. Chronic visible skin involvement can also affect self-esteem and social functioning, particularly in adolescent and adult patients. These broader impacts are increasingly recognised as important outcomes to assess alongside skin clearance in clinical practice. A holistic assessment approach supports more complete evaluation of treatment benefit.

Improved understanding of the Type 2 immune pathway has led to the development of targeted biologic therapies for patients with moderate-to-severe atopic dermatitis inadequately controlled by topical treatment. This represents a shift from broader immunosuppression toward more mechanism-specific treatment options. Treatment selection increasingly considers disease severity, prior treatment response and patient-specific factors. Ongoing research continues to refine phenotyping and treatment personalisation in atopic dermatitis.